EUVIMEDEUVIMED entdecken
Crossref

Effects of diet and gender on the pharmacokinetics of oral lenvatinib: A clinical trial in healthy Chinese participants

Yilin Wei, Yuan Yu, Wenyu Zhang, Hongli Mu, Kun He, Qing Wen, Xiaoran Zhang

Int. Journal of Clinical Pharmacology and Therapeutics · 2023

DOI: 10.5414/cp204440 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Int. Journal of Clinical Pharmacology and Therapeutics, 2023. Verfasst von Yilin Wei und 6 weiteren Autor:innen. Hauptthemen laut MEDLINE: East Asian People, Fasting. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Lenvatinib is a tyrosine kinase inhibitor that helps prevent angiogenesis. In this study, we investigated the potential influencing factors on lenvatinib pharmacokinetics to provide a reference for clinical application. MATERIALS AND METHODS: All healthy participants received a single dose of 4 mg lenvatinib mesylate capsules with a high-fat meal or fasted conditions. Lenvatinib plasma concentrations were determined via high-performance liquid chromatography-mass spectrometry/mass spectrometry, and the pharmacokinetic parameters were calculated using WinNonlin 8.1 software. A mixed effect model analysis was adopted to explore the influence factor for the pharmacokinetic parameters of lenvatinib. RESULTS: After a single oral dose of 4 mg lenvatinib mesylate, the pharmacokinetic parameters for the fasted and fed groups were as follows: tmax was 2.0 hours and 4.5 hours, Cmax was 53.60 ng/mL and 45.54 ng/mL, AUC0-t was 597.44 h×ng/mL and 561.51 h×ng/mL, CL was 6.82 L/h and 7.26 L/h, and Vd was 82.82 L and 94.04 L, respectively. Compared with those in the fasted group, decreased Cmax and increased tmax were observed in the fed group. The geometric mean ratios of fed/fasted for Cmax, AUC0-t, and AUC0-∞ were 86.9%, 94.0%, and 93.9%, respectively, and the pharmacokinetics of lenvatinib were significantly influenced by food intake. Gender influenced the pharmacokinetics of lenvatinib; females had higher Cmax and AUC0-t levels after 4 mg lenvatinib. Lenvatinib was well tolerated in healthy Chinese subjects. CONCLUSION: High-fat diet altered the pharmacokinetic profile of lenvatinib, but not sufficient to significantly impact its clinical efficacy. Therefore, lenvatinib is suitable for administration under fasted or fed conditions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

East Asian PeopleFastingFemaleHumansBiological AvailabilityHealthy VolunteersArea Under CurveCross-Over StudiesAdministration, OralPhenylurea CompoundsQuinolines

Substanzen

lenvatinibPhenylurea CompoundsQuinolines

Zitieren

APA

Wei, Y., Yu, Y., Zhang, W., Mu, H., He, K., Wen, Q., & Zhang, X. (2023). Effects of diet and gender on the pharmacokinetics of oral lenvatinib: A clinical trial in healthy Chinese participants. Int. Journal of Clinical Pharmacology and Therapeutics. https://doi.org/10.5414/cp204440

Vancouver

Wei Y, Yu Y, Zhang W, Mu H, He K, Wen Q, et al. Effects of diet and gender on the pharmacokinetics of oral lenvatinib: A clinical trial in healthy Chinese participants. Int. Journal of Clinical Pharmacology and Therapeutics. 2023. doi:10.5414/cp204440

BibTeX
@article{Wei2023,
  author = {Wei, Yilin and Yu, Yuan and Zhang, Wenyu and Mu, Hongli and He, Kun and Wen, Qing and Zhang, Xiaoran},
  title = {Effects of diet and gender on the pharmacokinetics of oral lenvatinib: A clinical trial in healthy Chinese participants},
  journal = {Int. Journal of Clinical Pharmacology and Therapeutics},
  year = {2023},
  doi = {10.5414/cp204440}
}
Kostenlos starten →